Tag: Diffuse Large B Cell Lymphoma
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Axi-cel more effective but tisa-cel less toxic in DLBCL
POLARIX: Novel regimen superior to R-CHOP in DLBCL
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL
Mutational analyses are predictive in malignant lymphomas
